Clinical Value of 18F-(2S,4R)-4-Fluoroglutamine PET/CT in Glioma
Although we do not assert that 18 F-FGln PET/CT imaging is satisfactory in the differential diagnosis of glioma, we revealed its potential for identifying the stage of gliomas and the IDH mutation status and propose that glutamine-based PET imaging enables the assessment of metabolic nutrient uptake of gliomas to assist clinical diagnosis and treatment of patients.
Authors
- Futao Liu (ORCID: https://orcid.org/0000-0003-4904-8411)
- Qing Xie
- Shouwei Li (ORCID: https://orcid.org/0000-0003-3320-2517)
- Heqian Zhao (ORCID: https://orcid.org/0000-0002-0027-5392)
- Zhi Yang (ORCID: https://orcid.org/0000-0003-2084-5193)
- Jianhua Yang (ORCID: https://orcid.org/0000-0003-2376-6167)
- Xiaoxia Xu
Institutions
- Capital Medical University (CN)
- Peking University (CN)
- National Medical Products Administration (CN)
- Peking University Cancer Hospital (CN)
- Beijing Sanbo Brain Hospital (CN)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1097/rlu.0000000000005581
- Citations
- 2
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.88